

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on November 7, 2005.

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

AMENDMENT UNDER 37 CFR
§1.825(a) THROUGH (c)
Patent Application
Docket No. C&R-102
Serial No. 10/537,142

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)
Art Unit : (Not yet assigned)
Applicants : Richard Joseph Fagan, Christopher Benjamin Phelps,
Tania Maria Rodrigues, Melanie Yorke, Mariastella De Tiani
Serial No. : 10/537,142
Filed : June 2, 2005
Confirm. No. : 1704
For : Splice Variant of the Human Pituitary Growth Hormone

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notification of Missing Requirements under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 C.F.R. §§1.821-1.825: